|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 272.11 USD | +0.99% |
|
+0.71% | +4.40% |
| Jan. 17 | Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks | MT |
| Jan. 17 | Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks | MT |
| Capitalization | 146B 141B 133B 119B 209B 12,610B 234B 1,613B 598B 5,202B 549B 537B 22,770B | P/E ratio 2024 * |
29.8x | P/E ratio 2025 * | 22.4x |
|---|---|---|---|---|---|
| Enterprise value | 196B 188B 178B 159B 280B 16,874B 313B 2,159B 800B 6,962B 734B 719B 30,470B | EV / Sales 2024 * |
5.9x | EV / Sales 2025 * | 5.53x |
| Free-Float |
99.75% | Yield 2024 * |
3.32% | Yield 2025 * | 3.54% |
More valuation ratios
* Estimated data
More news
Last Transcript: Amgen Inc.
More recommendations
More press releases
More news
| 1 day | +0.99% | ||
| 1 week | +0.71% | ||
| Current month | +4.40% | ||
| 1 month | +3.31% | ||
| 3 months | -15.40% | ||
| 6 months | -17.86% | ||
| Current year | +4.40% |
1 week
267.15
276.97
1 month
257.05276.97
Current year
257.05276.97
1 year
253.30346.85
3 years
211.71346.85
5 years
177.05346.85
10 years
130.09346.85
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 62 | 2012-04-30 |
Peter Griffith
DFI | Director of Finance/CFO | 66 | 2019-12-31 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 62 | 2018-07-25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 62 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 64 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 70 | 2002-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 145 M€ | +0.03% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.99% | +0.71% | -11.60% | +18.88% | 146B | ||
| -4.21% | -9.00% | +15.45% | +198.49% | 653B | ||
| -0.50% | +1.77% | -9.06% | -11.03% | 354B | ||
| -4.22% | -10.08% | -24.73% | +73.23% | 341B | ||
| -1.23% | -2.93% | +4.12% | +28.96% | 303B | ||
| -2.76% | -3.03% | -17.64% | +21.26% | 248B | ||
| +0.57% | +0.76% | +9.34% | -26.90% | 236B | ||
| -1.32% | -0.26% | +2.72% | +22.08% | 206B | ||
| -0.10% | -1.72% | -4.87% | +9.63% | 197B | ||
| -0.72% | -1.87% | -7.00% | -51.34% | 149B | ||
| Average | -1.35% | -1.83% | -4.33% | +28.33% | 283.38B | |
| Weighted average by Cap. | -1.96% | -3.21% | -1.98% | +56.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 33.18B 31.91B 30.12B 26.98B 47.51B 2,860B 52.99B 366B 136B 1,180B 124B 122B 5,165B | 34.4B 33.08B 31.23B 27.97B 49.26B 2,966B 54.94B 379B 141B 1,224B 129B 126B 5,355B |
| Net income | 4.99B 4.8B 4.53B 4.06B 7.14B 430B 7.97B 55.03B 20.39B 177B 18.71B 18.33B 777B | 6.26B 6.02B 5.68B 5.09B 8.96B 540B 10B 69.05B 25.59B 223B 23.48B 23B 975B |
| Net Debt | 49.46B 47.56B 44.9B 40.21B 70.83B 4,264B 78.99B 546B 202B 1,759B 186B 182B 7,700B | 43.84B 42.16B 39.8B 35.65B 62.78B 3,780B 70.02B 484B 179B 1,559B 164B 161B 6,825B |
More financial data
* Estimated data
Employees
26,700
Sector
Pharmaceuticals
Calendar
2025-02-04
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-17 | 272.11 $ | +0.99% | 3,244,290 |
| 25-01-16 | 269.43 $ | +0.18% | 2,684,500 |
| 25-01-15 | 268.94 $ | +0.69% | 3,737,536 |
| 25-01-14 | 267.10 $ | -1.14% | 2,942,309 |
Delayed Quote Nasdaq, January 17, 2025 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
272.11USD
Average target price
317.24USD
Spread / Average Target
+16.58%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
